In Duchenne Muscular Dystrophy (DMD), large clinical trials can only be possible as part of an international multicentric effort. A crucial question for the field is whether the centers involved in clinical trials and in natural history studies have similar standards of care, so that comparability of the data is guaranteed and the risk of bias reduced.
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?
Battini R
2016-01-01
Abstract
In Duchenne Muscular Dystrophy (DMD), large clinical trials can only be possible as part of an international multicentric effort. A crucial question for the field is whether the centers involved in clinical trials and in natural history studies have similar standards of care, so that comparability of the data is guaranteed and the risk of bias reduced.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
